{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-314167","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046838+00:00","generated_at":"2026-05-16T13:38:41.775888+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4D Molecular Therapeutics increases wet AMD trial enrollment to 480 patients for global regulatory submissions","bullets":["Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.","Amendments aim for ~90% power with ~4-letter noninferiority margin for non-FDA agencies (e.g., PMDA, EMA).","No impact on guided enrollment completion or financial runway into H2 2028; 4FRONT-1 topline expected H1 2027.","Asia-Pacific regulatory submissions supported by Otsuka partnership, leveraging global commercial opportunity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-314167","json":"https://secwatch.observer/filing/0001193125-25-314167.json","markdown":"https://secwatch.observer/filing/0001193125-25-314167.md","text":"https://secwatch.observer/filing/0001193125-25-314167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/0001193125-25-314167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:38:41.775888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}